Adderall, Vyvanse, and Concerta are the three most-prescribed ADHD stimulant brand names in the United States, but each works through a different mechanism, carries different patent and generic status in 2026, and costs a different amount depending on whether you choose the brand or generic. Adderall contains mixed amphetamine salts (four salt compounds) and has been fully generic for over a decade, making it the most affordable option for uninsured patients. Vyvanse (lisdexamfetamine dimesylate) is an amphetamine prodrug that Takeda brought to market in 2007; generic lisdexamfetamine became available in August 2023 from 15 FDA-approved manufacturers. Concerta (methylphenidate ER) uses an OROS osmotic delivery system; only one authorized generic maintains AB-rated equivalence to brand Concerta, which complicates substitution at the pharmacy counter.
All three drugs are Schedule II controlled substances under the Controlled Substances Act, which restricts DEA-regulated aggregate production quotas. Those quotas have directly caused and sustained the ADHD stimulant shortage that started in October 2022. The FDA and the American Society of Health-System Pharmacists (ASHP) continue to list mixed amphetamine salts (Adderall) and methylphenidate ER products as in shortage as of mid-2026, with intermittent availability gaps on specific dose strengths. The DEA increased amphetamine production quotas by approximately 14 percent in early 2026 and lisdexamfetamine quotas were also raised, which is gradually improving availability, but patients should call their pharmacy before assuming a given strength is in stock. Patients who qualify for Medicaid income limits generally pay $1 to $4 copays and face fewer access barriers than those paying cash.
Because all three drugs are oral, self-administered prescriptions filled at retail pharmacies, they are billed exclusively under Medicare Part D (not Part B). No HCPCS J-codes apply to any of them. None are included in the Inflation Reduction Act Round-1 or Round-2 Medicare price negotiations; they are not high-spend biologics that CMS selected for negotiation. Patients with commercial insurance can use manufacturer savings cards, but those cards are blocked by federal anti-kickback statute for anyone on Medicare, Medicaid, TRICARE, or VA benefits. Patients who are uninsured and income-eligible can apply to the Johnson and Johnson Patient Assistance Foundation for free brand Concerta, or use generic discount coupons as the most accessible cost-reduction tool for all three drugs. To review your Medicare eligibility or federal poverty level thresholds, see the linked guides.
What ADHD Stimulants 2026 Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same adhd stimulants 2026 can cost many times more at a hospital than at your local pharmacy:
2026 ADHD Stimulants 2026 Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Pharmacy counter (generic, cash, GoodRx coupon) | $15 - $85/month depending on drug | Generic Adderall IR: $15-$45. Generic lisdexamfetamine (Vyvanse): $60-$85. Generic methylphenidate ER (Concerta): $30-$57. |
| Pharmacy counter (brand, no insurance) | $300 - $558/month depending on brand | Brand Adderall XR: ~$415/month. Brand Vyvanse: $400-$558/month. Brand Concerta: $300-$545/month. |
| Medicare Part D (2026) | $0 - $80/month (plan-dependent), $2,100 annual OOP cap | All three stimulants covered for ADHD; generic tier placement lowers copays. Prior authorization is standard. $2,100 annual cap under the Inflation Reduction Act. |
| Medicaid | $1 - $4/prescription with PA | Covered in all 50 states for ADHD with prior authorization. State copay levels vary; generic preferred in most Medicaid formularies. |
| Commercial insurance (with savings card) | $4 - $30/month (program-specific) | Concerta savings card: $4/fill for eligible insured patients. Vyvanse Takeda card: as low as $30/month. Adderall XR brand: Takeda co-pay assistance. Not valid with government insurance. |
Retail and coupon prices reflect 2026 GoodRx, SingleCare, and pharmacy survey data. Part D costs depend on your plan's formulary tier. Walmart's $4 generic program does not apply to Schedule II controlled substances.
Source: GoodRx 2026, SingleCare 2026, CMS Medicare Part D, Janssen Concerta savings program
Why Hospitals Charge So Much
ADHD stimulants like Adderall, Vyvanse, and Concerta are almost always dispensed at retail pharmacies, not administered in hospital settings. However, when a patient is admitted to a hospital for any reason and continues their prescribed stimulant, the hospital may dispense the medication from its own formulary during the inpatient stay. In that case, the hospital bills the drug at its chargemaster rate, which is an internally set list price that includes the drug acquisition cost plus markups for controlled-substance storage compliance, pharmacy overhead, and nursing administration. Because all three drugs are Schedule II controlled substances, hospitals are required to maintain chain-of-custody logs, locked storage, and pharmacist verification for each dispensing event. These compliance costs drive the per-unit inpatient price well above retail pharmacy prices.
A generic Adderall tablet retailing for $0.50 to $1.50 per tablet at the pharmacy can appear on a hospital bill at $15 to $50 per tablet. Generic methylphenidate ER capsules costing under $2.00 at the pharmacy counter may be billed at $30 to $80 each in an inpatient setting. The markup is especially pronounced for extended-release formulations that require specialized OROS or multi-layer tablet technology that hospitals may not stock at formulary scale. If you see a line item for any ADHD stimulant on an inpatient bill, compare the per-unit charge to the 2026 GoodRx retail price for the specific dose and formulation. Any charge more than five times the retail generic price is a reasonable dispute target. Use the CoveredUSA Medical Bill Analyzer to flag discrepancies before paying.
Patient Assistance Programs
Patient assistance programs (PAPs) for ADHD stimulants vary significantly by brand. Generic Adderall IR is already inexpensive enough ($15 to $45 per month with GoodRx) that no income-based free-drug PAP is needed for the generic. The primary PAP options in 2026 for brand-name versions are: the Johnson and Johnson Patient Assistance Foundation for Concerta (free drug for income-eligible uninsured patients), the Concerta savings card for commercially insured patients ($4 per fill, $150 maximum benefit per 30-day supply), and the Takeda savings card for brand Vyvanse. Takeda discontinued the Help at Hand free-drug PAP for Vyvanse in October 2023. Uninsured patients without a qualifying PAP should rely on GoodRx or SingleCare discount coupons for generics as the best available cost reduction.
Patient assistance programs for ADHD Stimulants 2026| Manufacturer program | Cost / Benefit | How to apply |
|---|
| Johnson and Johnson Patient Assistance Foundation (JJPAF) - Concerta | Free brand Concerta for uninsured or underinsured patients with income at or below 400% FPL (approximately $63,840/year for a household of 1 in 2026) | jnjwithme.com |
| Concerta Savings Card (Janssen / commercially insured patients) | As little as $4 per fill for commercially insured patients ages 6-65; $150 maximum benefit per 30-day supply; maximum $1,800 or 12 fills per calendar year. Not valid with Medicare, Medicaid, TRICARE, or VA. | concerta.net/coupon.html |
| Takeda Vyvanse Savings Card (commercially insured patients) | As low as $30/month for brand Vyvanse; up to $60 off per fill. For commercially insured patients only. Not valid for Medicare, Medicaid, TRICARE, or other federal program beneficiaries. | vyvanse.com |
| GoodRx / SingleCare coupons (generic drugs, all income levels) | Generic Adderall IR: $15-$45/month. Generic lisdexamfetamine (Vyvanse): $60-$85/month. Generic methylphenidate ER (Concerta equivalent): $30-$57/month. No income requirement. Available to any patient regardless of insurance status. | goodrx.com |
Manufacturer savings cards (Concerta savings card, Takeda Vyvanse savings card) cannot be used by patients on Medicare, Medicaid, TRICARE, or VA benefits. This is required by federal anti-kickback statute (42 U.S.C. Section 1320a-7b), which bars manufacturers from providing financial incentives to federal health program beneficiaries. If you have Medicare or Medicaid, apply for the JJPAF income-based PAP for Concerta, or use GoodRx/SingleCare coupons for generic stimulants. There is no income-based free-drug PAP for uninsured Vyvanse patients as of 2026.
Source: Johnson and Johnson Patient Assistance Foundation (jnjwithme.com), Janssen Concerta savings program (concerta.net), Takeda Vyvanse savings (vyvanse.com), GoodRx 2026
Medicare Part D
Medicare Part D covers Adderall (mixed amphetamine salts), lisdexamfetamine (Vyvanse), and methylphenidate ER (Concerta) when prescribed for ADHD. None of these drugs fall under a protected drug class that Part D plans are required to cover broadly (protected classes are limited to cancer, HIV/AIDS, immunosuppressants, antidepressants, antipsychotics, anticonvulsants, and antiretrovirals). This means your specific Part D plan's formulary determines whether and at what tier each stimulant is covered. Generic versions are almost always preferred, and prior authorization is standard across Medicare Part D plans for stimulants.
Under the 2026 Medicare Part D benefit design, your total annual out-of-pocket spending across all covered Part D drugs is capped at $2,100. That cap comes from the Inflation Reduction Act of 2022 and replaced the prior catastrophic-phase coinsurance structure. Once you reach $2,100 in out-of-pocket Part D spending in a calendar year, your plan pays 100 percent for covered drugs for the rest of the year. There is no special monthly stimulant cap comparable to the $35 insulin cap: stimulants fall under the general Part D framework. Medicare beneficiaries cannot use manufacturer savings cards for any of these three drugs under federal anti-kickback law.
Formulary tier placement matters significantly for ADHD stimulants on Medicare Part D. Generic amphetamine salts (Adderall generic) are typically placed on Tier 1 or Tier 2, with copays often ranging from $0 to $10 per month. Generic lisdexamfetamine and generic methylphenidate ER products are typically Tier 2 or Tier 3, with copays from $5 to $47 per month depending on plan. Brand versions without generic substitution approved under Medicare are placed on Tier 3, Tier 4, or non-formulary, with higher cost-sharing or step therapy requirements. Checking your specific plan's 2026 formulary at medicare.gov or by calling your plan is the most reliable way to verify cost before filling.
Common ADHD Stimulants 2026 Billing Errors
ADHD stimulants are oral Schedule II drugs billed through Part D, not Part B. No HCPCS J-codes apply. Billing errors for these drugs are mostly at the pharmacy level rather than the hospital billing level:
- Brand billed when generic was dispensed: if the pharmacy fills with generic amphetamine salts or generic lisdexamfetamine but submits the claim as the brand, the patient is charged the higher brand-tier copay. Always verify what was dispensed against what appears on the receipt.
- Prior authorization denial billed directly to patient without filing a formal appeal. For Schedule II stimulants, PA denials are common and frequently overturned on appeal when medical necessity documentation is submitted. Patients should not pay cash for a PA-denied claim before exhausting the appeal process.
- For Concerta specifically: non-AB-rated generic methylphenidate ER billed at the same tier as AB-rated or brand Concerta. BX-rated generics (Mallinckrodt, Kremers Urban) may be treated differently by some plans. Confirm which generic manufacturer your pharmacy dispenses and verify the formulary tier assignment.
- Schedule II restriction on 90-day fills: most Part D plans and state Medicaid programs restrict ADHD stimulants to 30-day supplies per federal Schedule II rules. A claim submitted for 90 days will be rejected; patients may receive only 30 days but be billed incorrectly for a different quantity.
- Savings card not applied because pharmacist was not informed at time of fill. For Schedule II drugs, the prescription cannot be transferred to another pharmacy, so you cannot simply re-fill elsewhere to apply a coupon you missed. Present GoodRx or Concerta savings card to the pharmacist BEFORE the claim is processed.
Frequently Asked Questions
What is the cheapest ADHD stimulant in 2026, Adderall, Vyvanse, or Concerta?
Generic Adderall (mixed amphetamine salts IR) is the cheapest of the three in 2026, costing $15 to $45 per month with a GoodRx or SingleCare coupon at CVS or Walgreens. Generic methylphenidate ER (Concerta equivalent) is next at $30 to $57 per month with a coupon. Generic lisdexamfetamine (Vyvanse equivalent, available since August 2023) runs $60 to $85 per month with GoodRx. All three brands are significantly more expensive without a savings card or insurance. Your formulary tier under Medicare Part D or Medicaid also affects which is cheapest for you specifically.
Is there a generic for Vyvanse and Concerta in 2026?
Yes for both. Generic lisdexamfetamine dimesylate (Vyvanse equivalent) became available in August 2023 from 15 FDA-approved manufacturers; it costs $60 to $85 per month with GoodRx versus $400 to $558 for brand Vyvanse. For Concerta, the situation is more nuanced: several methylphenidate ER generics exist, but only the Patriot Pharmaceuticals authorized generic uses the OROS delivery technology and is rated AB (therapeutically equivalent) by the FDA. Other generics like those from Mallinckrodt are rated BX, meaning FDA found insufficient data to confirm they produce the same therapeutic effect. Discuss with your prescriber which generic is acceptable before substituting Concerta.
Does Medicare Part D cover Adderall, Vyvanse, and Concerta?
Medicare Part D covers all three stimulants for ADHD, but coverage is plan-specific. ADHD drugs are not in a protected drug class under Part D, so individual plans set their own formulary tiers and prior authorization requirements. Generic amphetamine salts (Adderall generic) are typically on Tier 1 or 2 with copays of $0 to $10 per month. Generic lisdexamfetamine and methylphenidate ER generics are usually Tier 2 or 3. The 2026 annual Part D out-of-pocket cap is $2,100. No special monthly stimulant cap exists. Check your specific plan's formulary at medicare.gov.
Can I use a manufacturer coupon or savings card with Medicare for ADHD stimulants?
No. Federal anti-kickback statute (42 U.S.C. Section 1320a-7b) bars manufacturer savings cards from being used by anyone covered by Medicare, Medicaid, TRICARE, or VA benefits. The Concerta savings card ($4 per fill) and the Takeda Vyvanse savings card are both for commercially insured patients only. Medicare patients should check the Medicare Extra Help (Low Income Subsidy) program, which can significantly reduce out-of-pocket costs for Part D drugs including stimulants. Apply for Extra Help at ssa.gov/extrahelp.
Is there a free ADHD medication patient assistance program for uninsured patients?
For Concerta: the Johnson and Johnson Patient Assistance Foundation (JJPAF) provides free brand Concerta for uninsured or underinsured patients with household income at or below 400% of the federal poverty level (approximately $63,840 per year for a single person in 2026). Apply at jnjwithme.com. For Vyvanse: Takeda discontinued the Help at Hand patient assistance program in October 2023. As of 2026, no income-based free-drug program exists for Vyvanse; uninsured patients should use generic lisdexamfetamine with GoodRx ($60 to $85 per month). For Adderall: the generic is already so inexpensive ($15 to $45 with GoodRx) that no income-based PAP is typically necessary.
What if my insurance denies coverage for my ADHD stimulant?
Start by requesting a written denial notice that states the exact reason and the plan's clinical coverage criteria. Then have your prescriber file a formal appeal with a Letter of Medical Necessity documenting your ADHD diagnosis. A peer-to-peer review between your prescriber and the plan's medical director often resolves prior authorization denials for stimulants. If step therapy is required, ask your prescriber to submit a step-therapy exception based on prior medication failure or medical contraindication. Escalate to external review through your state Department of Insurance if the internal appeal fails. While appealing, ask your prescriber for a 30-day bridge prescription and use a GoodRx coupon at the pharmacy.
Are ADHD stimulants affected by the IRA Medicare price negotiation?
No. The Inflation Reduction Act Medicare price negotiation program targets high-spend drugs without generic competition and sets a Maximum Fair Price for selected brands. Adderall, Vyvanse/lisdexamfetamine, and Concerta/methylphenidate ER are small-molecule oral drugs for which generics exist or are available, so CMS did not select them for negotiation. None were included in the Round-1 (Maximum Fair Price effective 2026) or Round-2 (effective 2027) Medicare negotiation cohorts. The primary cost protection for Medicare Part D patients remains the $2,100 annual out-of-pocket cap under the Inflation Reduction Act.
Why are ADHD stimulants still in shortage in 2026, and how does that affect cost?
ADHD stimulant shortages persist primarily because DEA-regulated production quotas for Schedule II amphetamine-class and methylphenidate-class drugs limit how much active ingredient manufacturers can produce each year. Rising ADHD diagnoses and prescribing have increased demand faster than DEA has expanded quotas. The DEA raised production quotas by approximately 14 percent in early 2026, improving availability for some strengths. Shortages primarily affect specific dose strengths at individual pharmacies rather than all products nationwide. When your prescribed strength is out of stock, call multiple pharmacies before assuming unavailability. Cost is affected because shortage-driven dispensing substitutions can change the generic manufacturer, potentially altering your formulary tier or requiring a new prior authorization.
